أمريكا أولى دفعات لقاح فايزر بيونتيك خبّأت مفاجأة غير متوقعة
sabq.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sabq.org Daily Mail and Mail on Sunday newspapers.
UNE providing vaccination training to help address public health emergency
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
U.S. hospitals try MAb squads, infusion sites to boost use of COVID-19 antibody drugs
The U.S. Department of Health and Human Services has so far delivered over 250,000 doses of the drugs to states and territories. The latest weekly statistics from HHS show that only 21% of delivered drug was used to treat patients, Michael Ganio, senior director of pharmacy practice and quality at the American Society of Health-System Pharmacists, told Reuters.
Written By:
Deena Beasley / Reuters | 4:52 pm, Dec. 16, 2020 ×
This illustration provided by the Centers for Disease Control and Prevention in January 2020 shows the 2019 Novel Coronavirus. This virus was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China. (CDC/TNS)
By Deena Beasley
Dec 16 (Reuters) - U.S. hospitals have been slow to embrace COVID-19 antibody drugs from Eli Lilly and Co and Regeneron Pharmaceuticals Inc that have been authorized to reduce the risk of hospitalization, U.S. officials said on Wednesday.
Demand for the therapies, which are given as a one-time intravenous infusion, has been disappointing, and hospitals should be using them more, Operation Warp Speed chief advisor Dr. Moncef Slaoui said on a conference call. The government program is distributing and allocating the drugs.
Healthcare systems say they have been slow to ramp up use of the antibodies due to extra levels of complexity during the pandemic - including requirements for quick diagnosis times and the need to isolate infectious patients.